3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Other hematologic neoplasm
1
Lymphoid
1
Dermatologic
1
CNS
1
Conditions
Squamous Cell Carcinoma of Head and Neck
3
Melanoma
3
Recurrence
2
Head and Neck Neoplasms
2
Carcinoma, Renal Cell
2
Triple Negative Breast Neoplasms
1
Skin Neoplasms
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Neuroblastoma
1
Neoplasms
1
Neoplasm Metastasis
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Leukemia, B-Cell
1
Leukemia
1
Kidney Neoplasms
1
Glioma
1
Ependymoma
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Merkel Cell
1
Interventions
Temozolomide
4
Surgical Procedures, Operative
2
Radiotherapy
2
Magnetic Resonance Spectroscopy
2
Gadolinium DTPA
2
Filgrastim
2
Erlotinib Hydrochloride
2
Congresses as Topic
2
2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole
2
vitespin
1
sargramostim
1
picropodophyllin
1
marizomib
1
imetelstat
1
gadobutrol
1
gadobenic acid
1
fluorodopa F 18
1
bempegaldesleukin
1
antineoplaston AS 2-1
1
antineoplaston A10
1
Yoga
1
Transurethral Resection of Bladder
1
Topotecan
1
Thiotepa
1
Ritonavir
1
Radiation
1
Peripheral Blood Stem Cell Transplantation
1
Perfusion Magnetic Resonance Imaging
1
O(6)-benzylguanine
1
Nivolumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Ependymoma
×
bempegaldesleukin
×
Clear all
NCT04730349
2023-03-24
PIVOT IO 020
Bristol-Myers Squibb
Phase 1/2
Terminated
15 enrolled
14 charts